Tobam Sells 315 Shares of Stryker Co. (NYSE:SYK)

Tobam cut its holdings in Stryker Co. (NYSE:SYK) by 26.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 891 shares of the medical technology company’s stock after selling 315 shares during the period. Tobam’s holdings in Stryker were worth $321,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Alhambra Investment Management LLC grew its position in shares of Stryker by 1.5% in the fourth quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company’s stock valued at $719,000 after purchasing an additional 29 shares in the last quarter. Capital & Planning LLC grew its holdings in Stryker by 3.6% during the 4th quarter. Capital & Planning LLC now owns 841 shares of the medical technology company’s stock valued at $304,000 after buying an additional 29 shares in the last quarter. Concord Wealth Partners increased its position in shares of Stryker by 2.2% during the fourth quarter. Concord Wealth Partners now owns 1,396 shares of the medical technology company’s stock valued at $503,000 after buying an additional 30 shares during the period. Avestar Capital LLC lifted its holdings in shares of Stryker by 1.1% in the third quarter. Avestar Capital LLC now owns 2,948 shares of the medical technology company’s stock worth $1,065,000 after buying an additional 31 shares in the last quarter. Finally, Union Savings Bank boosted its position in shares of Stryker by 1.0% in the fourth quarter. Union Savings Bank now owns 3,162 shares of the medical technology company’s stock valued at $1,138,000 after acquiring an additional 31 shares during the period. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Trading Down 1.2 %

NYSE SYK opened at $391.42 on Friday. The stock has a 50-day moving average of $377.25 and a 200-day moving average of $364.47. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The firm has a market cap of $149.22 billion, a PE ratio of 50.44, a price-to-earnings-growth ratio of 2.98 and a beta of 0.96.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the firm earned $3.46 earnings per share. As a group, sell-side analysts forecast that Stryker Co. will post 13.49 EPS for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.86%. The ex-dividend date is Monday, March 31st. Stryker’s payout ratio is 43.30%.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on SYK. StockNews.com cut shares of Stryker from a “buy” rating to a “hold” rating in a research note on Thursday, January 30th. JPMorgan Chase & Co. lifted their price objective on Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. Morgan Stanley upgraded Stryker from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $370.00 to $445.00 in a research note on Monday, December 2nd. Truist Financial lifted their price target on Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a research report on Thursday, January 30th. Finally, UBS Group upped their price objective on shares of Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $419.37.

Insider Activity

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.